Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

Ads

You May Also Like

Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

DUBLIN, IRELAND, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical ...

BioCryst Reports Third Quarter 2018 Financial Results

APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. ...

Checkpoint Therapeutics to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ:CKPT), a ...